AI and HealthTech are attracting serious investor attention. In its 2026 Global Family Office Report, UBS found that 65% of surveyed family offices were investing in AI-related opportunities, while 33% had allocations to AI-enabled healthcare. The survey offers a useful view of family-office priorities, though it does not tell us how all high-net-worth investors are deploying capital.
Healthcare provides a clear reason for that interest: AI can be applied to problems that already consume substantial time and resources, from analysing scans to supporting clinical research. The UK government reported in January 2026 that AI was assisting with one-third of NHS chest X-rays. That demonstrates real-world adoption of the technology. It does not mean every company developing it has a viable business.
For private investors, the useful question is therefore less “Is AI in healthcare growing?” and more “What has this particular company proved?”
Start with the clinical problem
A HealthTech company should be able to identify who uses its product, what problem it solves and how outcomes are measured. Faster analysis may sound attractive, but investors need to understand its effect on clinical decisions, staff workload or patient care.
Evidence should fit the claim. A demonstration, a pilot in a hospital and routine paid deployment represent very different stages of progress. Investors should ask which stage the company has reached and what must happen before it can expand.
Understand the route to revenue
The user of a product may not be the person or organisation paying for it. A clinician might benefit from a tool, while a hospital, insurer or research organisation makes the purchasing decision.
That distinction affects the sales cycle. Investors should examine who controls the budget, what approvals are required, how long procurement takes and whether early contracts can realistically be repeated elsewhere. A promising pilot is valuable evidence, but it should not be presented as established recurring revenue.
Test the AI advantage
A company needs to explain why AI makes its product better and what protects that advantage. Questions include whether it has lawful access to suitable data, how the product performs outside its original test setting, and whether customers could achieve a similar result with widely available tools.
In healthcare, accuracy alone is not the whole assessment. Investors should also ask how the system handles errors, how people oversee its output and what evidence supports safe use in practice.
Follow the milestones, not the headline
HealthTech businesses can require years of product development, validation and commercial work. Their funding needs may change as they move from a prototype to a regulated product and then to broader adoption.
A useful investment assessment connects the capital being raised to specific milestones: a completed study, a required approval, a paid deployment or evidence that customers renew. It also asks how much additional funding the company may need if those milestones take longer than expected.
AI and HealthTech offer a wide range of potential opportunities, but sector enthusiasm cannot establish the merits of an individual investment. The strongest cases will show credible evidence of clinical value, a workable route to customers and a clear account of the risks still to be resolved.